Abstract
Australia is well positioned to conduct clinical trials in phage-based technology. Despite challenges with translating phage therapy to mainstream medicine, our regulations are designed for safe and innovative development. Recent success indicates that Australia is ideal for conducting further phage clinical trials. There are also expert clinical research organisations and generous tax incentives.
Subject
Microbiology (medical),Public Health, Environmental and Occupational Health,Applied Microbiology and Biotechnology,Microbiology
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献